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Abstract Irritable bowel syndrome (IBS) is one of the most common diseases of the gastrointestinal tract. IBS may
represent a primarydisorder of gastrointestinalmotility, accompaniedwithmotordysfunction in various extraintestinal
sites.Recent studies suggest that IBS is associated with bronchial hyper-responsiveness and bronchial asthma might be
moreprevalentin IBSpatients thanincontrolsubjects.The aimofour studywasto assess theprevalenceof IBSinacohort
of asthmatic patients.We evaluated150 patients with bronchial asthma (71males and 79 females, aged 45.1714.9 years)
and two control groups including130 patients with other pulmonary disorder and120 healthy subjects. All subjects en-
rolled (asthmatic and controls) completed the Greekversion ofthe Bowel Disease Questionnaire (BDQ).BDQis a, pre-
viously validated, self-report instrument to measure gastrointestinal symptoms.Diagnosis of IBSwas based on Rome II
criteria.The IBS prevalence was significantly higher in asthmatics (62/150,41.3%) than in subjects with other pulmonary
disorders (29/130, 22.3%, Po0.001) andhealthyones (25/120, 20.8%, Po0.001).For all subjects studied, the prevalence of
IBSwas significantly higher in females (78/214, 36.4%) than inmales (38/186, 20.4%, Po0.001).The IBS prevalence in asth-
matic males was 29.5% vs.15.2% in male patients with other pulmonary disorders (P=0.002) and 14.2% in male healthy
subjects (P=0.002).The IBSprevalence in asthmatic femaleswas 51.8% vs. 28.1% in femalespatientswith otherpulmonary
disorders (Po0.001) and 26.5% in females healthy subjects (Po0.001).None of the asthmamedicationswere associated
with increased or decreased likelihood of IBS.We conclude that patients with bronchial asthma have an increased pre-
valence of IBS. Further studies are needed to clarify the potential pathogenetic mechanisms underlying the association
between IBS and asthma.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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Irritable bowel syndrome (IBS) is a functional disorder
consisting of altered bowel habits, abdominal pain and
the absence of any detectable organic pathologic pro-
cess. It is recognizedwidely as one of themost common
gastrointestinal disorders. Symptoms consistent with
IBS are reported by15^20% of the general population (1)
and IBS accounts for 50% of all referrals to gastroenter-
ologists (2). Because of absenteeism fromwork and hos-
pitalization this syndrome imposes a substantial
economic burden on society (3).
Despite the clinical and socioeconomic importance,
the etiology and pathophysiology of IBS remain unclear.
The currentconcept is that IBSrepresents a primarydis-
order of gastrointestinal motility (4). It is well known
that any part of gastrointestinal systemmaybe involved,
as gastroesophageal re£ux disease (5) and motor disor-Received 28 December 2001; accepted in revised form 27May 2002
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E-mail: roumar26@yahoo.comders of the esophagus (6) and small intestine (7) are com-
mon ¢ndings in patients with IBS. In IBS patients motor
dysfunction has also been observed in extraintestinal
sites including genitourinary and vascular system. It has
been suggested that 33^50% of patientswith IBS experi-
encerecurrenturinary symptomsdue tomotor abnorm-
alities of the bladder (8). Moreover, sexual dysfunction,
including dyspareunia and inhibited sexual desire, has
been shown to be 5^15 times more common in IBS sub-
jects, comparedwith patients su¡ering from organic bo-
wel disease (9). Recently, IBS has also been associated
with primary ¢bromyalgia (10).The existence of a gener-
alized abnormality involving smoothmuscle and/or auto-
nomic nervous system has been suggested to explain all
these associations.This abnormalitymightberesponsible
for both gastrointestinal and extragastrointestinal
symptoms in patients with IBS.
Association of IBS with bronchopulmonary disease
was initially suspected in1991, whenWhite et al. showed
that IBS patients had an increased prevalence of bron-
chial hyper-responsiveness (11). Seven years later, a study
in a randomly selected community sample showed that
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bronchial hyper-responsiveness (12). More recently, it
has been reported that bronchial asthma might bemore
prevalent in IBS patients than in control subjects (13). As
far as we know, there are no studies focused on the pre-
valence of IBS symptoms in patients with bronchial asth-
ma.
In order to investigate the relation between IBS and
bronchial asthma, we assessed the prevalence of IBS
symptoms in a cohort of asthmatic patients and control
subjects.
METHODS
Patients selection
The present study was conducted at the 9th Depart-
mentof PulmonaryMedicine, in‘‘Sotiria’’ Chest Diseases
Hospital (Athens, Greece). The local ethics committee
approved the study and written informed consent was
obtained from each participant. Following a prede¢ned
protocol, between September 1, 1998 and September
30, 2001,198 consecutive patientswith bronchial asthma,
both newly referred and follow-up, were recruited from
the outpatient clinics. In all cases, diagnosis of bronchial
asthmawas based on the AmericanThoracic Society cri-
teria (14).Brie£y, bronchial asthmawas diagnosed as Ithe
presence of symptoms of episodic wheezing, cough and
shortness of breath responding to bronchodilators and
reversible air£ow obstruction documented in at least
one previous pulmonary function studyI. Exclusion cri-
teria were: (i) an acute asthma exacerbation the month
prior to study, (ii) a known organic bowel disease and (iii)
a previous abdominal surgery. A total of 48 patientswere
excluded from the study. Twenty-three of them had un-
dergone a previous abdominal surgery (appendectomy:
18 cases, cholecystectomy: four and hysterectomy:
one), and 20 had an acute asthma exacerbation the
month prior to study. Moreover, ¢ve patients su¡ered
from known organic bowel diseases (in£ammatory bo-
wel disease: two cases, diverticular disease of the colon:
two and celiac sprue: one).Therefore,150 patients were
eligible for analysis.
Control subjects selection
Two control groupswere surveyed.The ¢rst included130
patients with other pulmonary disorders, attending the
outpatient clinics during the period of the study (chronic
obstructive pulmonary disease: 62 patients, respiratory
infections: 45, pulmonary tuberculosis: 10, sarcoidosis:
13).The second group included120 healthy subjects who
attended courses designed for public health education,
during the same period. Subjects with a known history
of gastrointestinal tract pathology were not included inthe control groups.Control subjects werematchedwith
the asthmatics for sex and age (within 2 years).
Asthmamedication useFlung function
In all asthmatic patients current asthma medication use
was recorded.Patients were speci¢cally asked about the
use of theophylline preparations, b-agonists, ipratro-
piumbromide, inhaled or oral corticosteroids, cromolyn
and ketotifen. Moreover, in all cases spirometric values
(FEV1, FVC and FEV1/FVC) were measured using a dry
spirometer (Vica-test,Mijhardt,Holland).The best value
of three maneuvers was expressed as a percentage of
the predicted value.
IBS evaluation
IBS symptom was evaluated using the Bowel Disease
Questionnaire (BDQ). The BDQ was developed as a
self-report instrument to measure gastrointestinal
symptoms experienced over the prior1year and to facil-
itate the diagnosis of functional gastrointestinal illness,
including IBS. This questionnaire has been validated (15)
and extensively applied in epidemiological studies in the
United States and Europe (16^18). Previous testing has
shown this instrument to be reliable, with a median k-
statistic for symptom items of 0.78 (interquartile range
0.52^1.0), as well as having adequate content, predictive
and construct validity in the outpatient setting. The
BDQ was translated into Greek and an authorized
translator trained in gastrointestinal terminology
checked the translation. All subjects (patients and con-
trols) completed the Greek version of the BDQ.To con-
¢rm the reliability of the Greek version of the BDQ, 50
subjects from the study population were also asked to
complete this version on two separate occasions. The
median time between completion of the surveys was 50
days (range 15^85).Of the symptom items, all were sig-
ni¢cantly reliable and most questions produced well to
excellent agreement in the tested subjects. The median
kappa statistic for the symptom items was 0.70 (inter-
quartile range 0.47^1.00).
Diagnosis of IBSwasbased onRome II criteria (19).The
Rome II criteria required the existence of abdominal dis-
comfort or pain for at least12 weeks, which need not to
be consecutive, in the preceding12 months.The discom-
fort or pain should be characterized by at least two of
the following three features: (i) relief with defecation,
(ii) onset associated with a change in frequency of stool
and (iii) onset associated with a change in form (appear-
ance) of stool.
Statistical analysis
Results are expressed asmean7 one standard deviation
(7SD).Signi¢cance of di¡erence between groups was
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ables and w2-test for proportions. Associations between
binary variables were tested using Fisher’ s Exact Test.
The statistical analysis was performed using the SPSS
program (SPSS Inc, IL, U.S.A.) and P-values were two-
tailed analyzed. P values of less than 0.05 were consid-
ered statistically signi¢cant.
RESULTS
The demographic data of both asthmatic patients and
controls are shown inTable 1. The mean age and gender
ratios of the asthmatics did not di¡er signi¢cantly from
those of the control groups.Table1shows also the spiro-
metric values of patients with bronchial asthma.
The prevalence of IBS in asthmatic patients and con-
trols is shown inTable 2. The IBS prevalence was signi¢-
cantly higher in asthmatics (41.3%) than in subjects with
other pulmonarydisorders (22.3%,Po0.001) andhealthy
ones (20.8%,Po0.001).Most of the asthma patients used
b-agonists (142 patients, 94,6 %) and inhaled corticoster-
oids (122 patients, 81%). Only 48 (32%) and 46 patients
(30.6%) used oral corticosteroids and theophylline pre-
parations respectively. Neither corticosteroids (inhaled
and oral), nor theophyllinepreparationswere associated
with increased or decreased likelihood of IBS.Moreover,
no statistically signi¢cant di¡erence, as regards the
spirometric values, was detectedbetween asthmatic pa-
tients with IBS (FEV1/FVC: 64.9711.6) and thosewithout
IBS (FEV1/FVC: 65.7712.2, P40.05).
For all subjects studied, irrespective of whether they
were asthmatics or controls, the prevalence of IBS was
signi¢cantly higher in females (78/214, 36.4%) than in
males (38/186, 20.4%, Po0.001) (Table 2).The IBS preva-
lence in asthmatic males was 29.5% vs.15.2% inmales pa-
tients with other pulmonary disorders (P=0.002) and
14.2% inmales healthy subjects (P=0.002).The IBS preva-
lence in females with asthma was 51.8% vs. 28.1% in fe-
males patients with other pulmonary disordersTABLE 1 Demographic data of asthmatics and controls
and spirometric values of asthmatic patients
Asthmatics Other
disorders
Healthy
subjects
(n=150) (n=130) (n=120)
Age, y 45.1714.9 48.6713.2 44.1715.1
Male/female 71/79 59/71 56/64
FVCa 88.2718.6
FEV1a 71.3721.4
FEV1/FVCa 65.5712.0
aExpressed as percentages of the predictedvalues.(Po0.001) and 26.5% in females healthy subjects
(Po0.001).
DISCUSSION
Data in the literature on the relationship between bron-
chial asthma and IBS are poor. A previous study, in a rela-
tively small sample of IBS patients, has shown an
increased prevalence of bronchial hyper-responsiveness
(11). Bronchial hyper-responsiveness is de¢ned as exces-
sive airway constriction in response to an inhaled stimu-
lus. It is a ubiquitous ¢nding in asthmatic patients andhas
been incorporated into recent de¢nition of bronchial
asthma (19). Recently, Kennedy et al. carried out a ques-
tionnaire-based study in a randomly selected community
sample of 4432 adults.They showed that: (i) symptomatic
bronchial hyper-responsiveness, gastroesophageal re£ux
disease and IBS occur together more often than ex-
pected and (ii) these conditions are independently asso-
ciated with each other (12). More recently, Yazar et al.
studied 133 patients with IBS and showed that 15.8% of
them had bronchial asthma according to history, clinical
¢ndings and values of pulmonary function test (13).
Our study is the ¢rst focused on the prevalence of IBS
in a population of patients with bronchial asthma. Ac-
cording to our results, the IBS prevalence in asthmatic
patients is signi¢cantly higher than that of the control
subjects.The detected IBS in healthy controls (20.8%) is
comparablewithreportedprevalence inprevious studies
concerning the general population (1). The preponder-
ance of women,which characterizesboth IBS asthmatics
and IBS controls, is also awell documented, although un-
explained yet, feature of all functional gastrointestinal
disorders (20).
We considered consumption of asthma medication as
a potential confounding factor in our study. Antiasth-
matic agents could produce symptoms indistinguishable
from those of IBS (theophylline preparations) (21), or
evenmask symptoms of an existed IBS (oral corticoster-
oids) (22).However,we showed thatneither corticoster-TABLE 2 Prevalence of IBS in asthmatic patients and
control subjects
Asthmatics Other
disorders
Healthy
subjects
Sample size 150 130 120
Total IBS 62 (41.3%) 29 (22.3%) 25 (20.8%)
Totalmales 71 59 56
Male IBS 21 (29.5%) 9 (15.2%) 8 (14.2%)
Total females 79 71 64
Female IBS 41 (51.8%) 20 (28.1%) 17 (26.5%)
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decreased likelihood of IBS. Unfortunately, due to the
widespread use of b-agonists, we cannot exclude the
possibility that these agentsmight represent such a con-
founding factor. b-agonists may in£uence small bowel
motility and produce symptoms indistinguishable from
those of IBS, as it iswell known thatmotor abnormalities
of small bowel represent a common ¢nding in IBS pa-
tients (23).
The present study has not focused on the potential
pathogeneticmechanisms underlying the association be-
tween IBS and bronchial asthma.This association might
re£ect either a kind of causal relationship between these
diseases or susceptibility inducedby common factors. As
far as we know, there are no data in the literature sup-
porting a causal relationship between asthma and IBS.
On the other hand, we cannot rule out the possibility
that an, unidenti¢ed yet, disorder a¡ecting both gastro-
intestinal tract and respiratory system may be impli-
cated in the susceptibility to both IBS and asthma. It is
well known that these two, seemingly disparate, condi-
tions share several common pathogenetic features. An
altered contractility and smooth muscle tone have been
observed inboth diseases (24).Moreover, recent studies,
concerning the altered vagal activity in IBS patients,
showed that the expression of IBSmight re£ect an auto-
nomic imbalance, perhaps stemming from disturbed hy-
pothalamic function (25). Although the role of the
autonomic nervous system in thepathogenesis of asthma
has not been clari¢ed yet, a generalized autonomic im-
balance might also result to inappropriate bronchocon-
striction as a response to an inhaled stimulus (26).
Therefore, asthma and IBSmay represent subsets of the
same entity.This entity could be a primary neuromuscu-
lar disorder producing respiratory, gastrointestinal
symptoms and, in a relatively large proportion of pa-
tients, both of them.
This hypothesis is further supportedby the, observed
in previous studies, high prevalence of gastroesophageal
re£ux disease in both asthma and IBS.Gastroesophageal
re£ux disease and IBS often coexist. It has been sug-
gested that a primary autonomic dysfunction might be
responsible for the coexistence of these two functional
gastrointestinal disorders (5). Recent studies based on
clinical symptoms, endoscopic esophagitis and 24-h am-
bulatory esophageal pH recordings showed gastroeso-
phageal re£ux disease to bemore prevalent in asthmatic
patients than in control subjects (27,28). A large propor-
tion of asthmatic patients with gastroesophageal re£ux
disease has also evidence of autonomic dysfunction with
primarily hypervagal responsiveness (29). However, the
existence of a neuromuscular disease a¡ecting both gas-
trointestinal tract and respiratory systemremains only a
hypothesis.We can not exclude thepossibility that other
factors may be responsible for the observed association
between IBS and asthma.In conclusion, the present study suggests that patients
with bronchial asthma have an increased prevalence of
IBS. Our results must be con¢rmed in a larger number
ofpatients.Further studies shouldbeundertaken to clar-
ify the pathogenetic mechanisms underlying the possible
association between IBS and asthma.
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